Last edition
News about "D-VRd regimen "
Johnson & Johnson Submits sBLA to FDA for Approval of DARZALEX FASPRO-Based Quadruplet Regimen
The CEPHEUS study evaluated the efficacy and safety of D-VRd compared to bortezomib, lenalidomide and dexamethasone (VRd) for NDMM patients for whom ASCT was not planned as initial therapy.
D-VRd Regimen | 01/10/2024 | By Aishwarya | 240
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members